Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medplus Health Services subsidiary Optival Health Solutions Private Limited has received two drug license suspension orders from the Drugs Control Administration in Karnataka. The first order suspends the license for a store at Kalidasa Layout for three days (order received May 11, 2026) with a potential revenue loss of Rs 0.64 lakhs. The second order suspends the license for a store at Mg Road, Chikkamagaluru for two days with a potential revenue loss of Rs 2.07 lakhs. Both suspensions are pursuant to Rule 65 of the Drugs and Cosmetics Act, 1940. The total quantifiable revenue impact is Rs 2.71 lakhs, which is relatively minor.
The suspension of two store licenses in Karnataka will result in temporary operational disruption at these locations. The total potential revenue loss of Rs 2.71 lakhs is negligible for a company of Medplus's scale and is unlikely to have any material impact on the stock price or investor sentiment.